<!DOCTYPE html>
<html>
    <head>
        <meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge"/>
        <script src='echarts.min-4.8.0.js'></script>
        <script src='echarts-wordcloud.min.js'></script>
    </head>
    <body>
        <style>
            html, body, #main {
                width: 100%;
                height: 100%;
                margin: 0;
            }
        </style>
        <div id='main'></div>
        <script>
            var chart = echarts.init(document.getElementById('main'));
            var keywords = {"Evaluation tools":1,
"Internet":1,
"Patient information":1,
"Quality":1,
"Thyroid cancer":27,
"Multiple primary neoplasms":1,
"Neoplasms":4,
"Pancreas":1,
"Prognosis":2,
"Second primary neoplasms":1,
"CXCL12":1,
"CXCR4":1,
"NF-κB":1,
"SDF-1":1,
"carcinome papillaire de la thyroïde":1,
"papillary thyroid carcinoma":18,
"KLK7":1,
"lncRNA-NEAT1":1,
"miR-129-5p":1,
"papillary thyroid cancer":5,
"Geographic locations":1,
"Incidence":3,
"Korea":1,
"Small-Area Analysis":1,
"Biopsy, fine-needle":1,
"Thyroid cancer, papillary":1,
"Thyroid nodule":7,
"Ultrasonography":5,
"Thyroid-like orbitopathy":1,
"complete ophthalmoplegia secondary to metastatic melanoma treatment":1,
"normal extraocular muscles":1,
"ophthalmoplegia with ipilimumab and nivolumab":1,
"Cancer":6,
"Medullary thyroid carcinoma":4,
"Multiple endocrine neoplasia type 2":1,
"Pheochromocytoma":1,
"RET proto-oncogene":1,
"Cancer prevalence":1,
"Italy":1,
"Projections":1,
"Survivors":1,
"Laryngectomy":1,
"Olfactory rehabilitation":1,
"Provox voice prosthesis":1,
"Questionnaire survey":1,
"Self-administered Odor Questionnaire (SAOQ)":1,
"Bone morphogenetic protein 4":1,
"Cell proliferation":2,
"Colony formation":1,
"MicroRNAs":1,
"Thyroid carcinoma":6,
"miR340-5p":1,
"Cytodiagnosis":1,
"Diagnostic imaging":1,
"Fine needle aspiration cytology":1,
"Thyroid neoplasms":8,
"Chinese Han people":1,
"Prevention":1,
"Risk factor":1,
"Vitamin D":1,
"Differentiated thyroid cancer":4,
"Evening sample":1,
"L-T4 posology":1,
"Morning sample":1,
"TSH":4,
"AR":1,
"Breast neoplasm":1,
"Manifestations":1,
"Molecular pathology":1,
"Recurrence":7,
"131I SPECT/CT":1,
"131I planar whole-body scan":1,
"long-term follow-up":1,
"neck and distant metastases":1,
"papillary thyroid microcarcinoma (PTMC)":1,
"serum thyroglobulin":1,
"thyroid/parathyroid":2,
"ultrasound":5,
"Bioinformatics analysis":1,
"Key genes":1,
"Conservative therapy":1,
"Risk management":1,
"Surgery":3,
"Children":1,
"Iodine status":1,
"Pregnant women":1,
"Thyroid volume":1,
"Urine iodine":1,
"Everolimus":2,
"Medullary thyroid cancer":3,
"Neuroendocrine Tumours":1,
"Pasireotide":1,
"American Thyroid Association guidelines":1,
"head and neck":2,
"lymph node surveillance":1,
"pediatrics":2,
"thyroidectomy":6,
"follicular":2,
"intrahepatic cholangiocarcinoma":1,
"papillary":1,
"thyroid neoplasm":5,
"thyroid-like":1,
"SEER":2,
"clinical trial":2,
"outcome":1,
"pan-cancer":1,
"prior cancer":1,
"survival":4,
"MYO1F":1,
"TCO locus":1,
"mitochondrial network":1,
"non-medullary thyroid carcinoma":1,
"whole exome sequencing":1,
"BRAF mutation":1,
"immunocytochemistry":1,
"molecular testing":1,
"plump cells":1,
"thyroid malignancies":1,
"thyroid nodules":3,
"Follicular thyroid cancer":1,
"Great veins invasion":1,
"Internal jugular vein":1,
"Thrombosis":1,
"adolescents and young adults":1,
"disease-specific symptoms":1,
"health-related quality of life":2,
"survivorship":1,
"CT":1,
"lymph node":1,
"metastasis":2,
"differentiated thyroid carcinoma":4,
"iodine-131":2,
"radioactive iodine":2,
"CT: computed tomography":1,
"LDH: lactate dehydrogenase":1,
"Pleural effusion":1,
"TSH: thyroid-stimulating hormone":1,
"TSHoma: thyroid-stimulating hormone (TSH)-secreting pituitary adenoma":1,
"fT4: free thyroxine":1,
"hypothyroidism":1,
"methimazole":1,
"pituitary neoplasms":1,
"neurological monitoring":1,
"residual thyroidectomy":1,
"false-positive":1,
"follicular-pattern lesions":1,
"noninvasive follicular thyroid neoplasm with papillary-like nuclear features":2,
"thyroid FNA":1,
"Anti‐CTLA 4":1,
"Anti‐PD1":1,
"Ipilimumab":1,
"Nivolumab":2,
"Pembrolizumab":2,
"Thyroid":12,
"Follicular variant of papillary thyroid carcinoma":1,
"Lymph node metastases":1,
"Ectopic thyroid":1,
"Lingual thyroid":1,
"Papillary carcinoma":1,
"Transoral surgery":1,
"Dilated cardiomyopathy":1,
"Iodide transport defect":1,
"NIS":2,
"RNA splicing":1,
"Thyroid scintigraphy":1,
"hand-foot skin reaction":1,
"overall survival":3,
"sorafenib":3,
"thyroid-stimulating hormone":1,
"thyroxine":2,
"biomarker":3,
"circular RNA":1,
"extrathyroidal extension":1,
"lymph node metastasis":4,
"18F-FDG":1,
"99mTc-sestamibi":1,
"Negative imaging":1,
"Radioiodine":2,
"Rising thyroglobulin":1,
"fish":1,
"5α-dihydrotestosterone supplement":1,
"Estradiol":1,
"Reductive 17β-hydroxysteroid dehydrogenases":1,
"Steroid sulfatase":1,
"ASCL1":1,
"NFIB":1,
"SCLC":1,
"TTF-1":1,
"neuroendocrine differentiation":1,
"Carcinome papillaire thyroïdien":1,
"Carcinome peu différencié":1,
"DICER1":1,
"Poorly differentiated thyroid carcinoma":2,
"Post radiation":1,
"Radiations nucléaires":1,
"Solid variant":1,
"Variante solide":1,
"BC survivors":1,
"Epidemiology, and End Results database":1,
"HR and HER2 subtypes":1,
"Subsequent colorectal and thyroid cancer":1,
"Subsequent ovary/uteri cancer":1,
"Surveillance":2,
"cyclin-dependent kinase":1,
"roniciclib":1,
"well-differentiated thyroid cancer":1,
"lymph node metastasis (LNM)":1,
"papillary thyroid cancer (PTC)":1,
"proteomic analysis":1,
"serum-purified exosomes (SPEs)":1,
"AJCC":1,
"differentiated":1,
"stratification":1,
"active surveillance":1,
"shared decision making":1,
"neoplasia":1,
"obesity":2,
"oncogene":2,
"Biomarkers":1,
"Breast neoplasms":1,
"Thyroid hormone receptor":1,
"Tumor suppressor proteins":1,
"Esophageal squamous cell carcinoma":2,
"Immunohistochemistry":2,
"Tumor necrosis factor receptor 2":1,
"B-mode ultrasonography":1,
"Multi-modality":1,
"Radiomics":2,
"Strain elastography ultrasonography":1,
"B-type Raf (BRAF)":1,
"Hashimoto's thyroiditis":1,
"diffuse lymphocytic infiltration":1,
"thyroid peroxidase antibody":1,
"Breast cancer":6,
"Circulating tumor cells (CTCs)":1,
"Esophageal cancer":1,
"Gastric cancer":2,
"Lung cancer":3,
"Negative enrichment-fluorescence in situ hybridization (NE-FISH)":1,
"CPT1A":1,
"Lymphangiogenesis":1,
"VEGF-C and VEGF-D":1,
"VEGFR-3":1,
"5-Fluorouracil":1,
"Chemoradiotherapy":1,
"Cisplatin":1,
"Docetaxel":1,
"NDAT":1,
"Oral cancer":1,
"PD-L1":1,
"Proliferation":4,
"bioethics":1,
"early detection":1,
"medical imaging":1,
"objectivity":1,
"overdiagnosis":1,
"preventive medicine":1,
"screening":1,
"IL6":1,
"PLX4032":1,
"STAT3":1,
"Tocilizumab":1,
"dosimetry":1,
"lithium":1,
"fine-needle aspiration":3,
"hyperparathyroidism":1,
"washout":1,
"Biologic parameters":1,
"Fatigue":1,
"Quality of life":2,
"Renal cancer":1,
"Sexual disorders":1,
"Gender":1,
"Bone mineral density":2,
"TSH suppression therapy":1,
"Trabecular bone score":1,
"nuclear factor-κB p50":1,
"nuclear factor-κB p65":1,
"quantitative real-time reverse transcription–polymerase chain reaction":1,
"Children and adolescents":2,
"Pulmonary metastases":1,
"Radioactive iodine therapy":1,
"Tumor doubling time":1,
"meta-analysis":3,
"myotonic dystrophy":1,
"nucleotide repeat disorders":1,
"Anti-cancer":1,
"Anti-inflammatory agent":1,
"Docking":1,
"Indicaxanthin":1,
"MM-GBSA":1,
"Molecular dynamics":1,
"Neuromodulator":1,
"Pharmacophore modeling":1,
"Phytochemicals":1,
"Reverse screening":1,
"HORMAD2":1,
"5-aza-2′-deoxycytidine":1,
"DNA methylation":2,
"Body mass index":1,
"early life":1,
"Calcification":1,
"Ectopic pituitary adenoma":1,
"Suprasellar":1,
"TSH-secreting":1,
"Clinical research":1,
"Lenvatinib":3,
"Molecular biology":1,
"Vascular endothelial growth factor":1,
"Adrenal failure":1,
"Diabetes":1,
"Dyslipidemia":1,
"Dysthyroidism":1,
"Hypophysitis":1,
"Immunotherapy":5,
"MTOR inhibitors":1,
"Tyrosine kinase inhibitors":2,
"Antigen":1,
"Cancer survivor":1,
"Immunology":1,
"Pancreatic neoplasm":1,
"Vaccination":1,
"Carcinogen classification":1,
"Follicular thyroid tumors":1,
"Human relevance":1,
"Non-genotoxic chemicals":1,
"Rodent tumors":1,
"Species differences":1,
"Thyroid hormones":1,
"Epidermal growth factor receptor":1,
"Predictive biomarker":1,
"Risk stratification":1,
"β-Catenin":1,
"CD152":1,
"CTLA-4":1,
"Follicular thyroid carcinoma":1,
"Polymorphism":1,
"Single-nucleotide":1,
"rs231775":1,
"rs5742909":1,
"head and neck endocrine surgery":1,
"thyroglossal duct cyst":1,
"Follicular variant papillary thyroid carcinoma":1,
"iodine radioisotopes":2,
"neoplasm recurrence":1,
"therapy":1,
"treatment outcome":1,
"ICAM-1":1,
"miR-335-5p":1,
"miRNAs":1,
"Gynecological risks":1,
"Pregnancy complications":1,
"Reproductive risks":1,
"Thyroid cancer survivors":1,
"Palpation":1,
"Thyroglobulin":2,
"dynamic risk stratification":1,
"prognostic factors":1,
"stimulated postoperative thyroglobulin":1,
"Tc-99m MIBI":1,
"nodules":1,
"side effects":1,
"thyroiditis":1,
"activating TSHR mutation":1,
"goiter":1,
"non-autoimmune hyperthyroidism":1,
"indeterminate cytology":2,
"C-myc":1,
"Liver cancer stem cell":1,
"PKM2":1,
"miR675":1,
"AJCC staging":1,
"age":2,
"fine-needle aspiration cytology":1,
"giant cell tumor":1,
"secondary thyroid neoplasm":1,
"outcomes":1,
"pediatric differentiated thyroid carcinoma":1,
"radioiodine therapy":1,
"Bosniak classification":1,
"Contrast-enhanced ultrasound":1,
"Cystic renal lesions":1,
"Image fusion":1,
"Renal cell carcinoma":1,
"Artemisia annua L":1,
"autophagy":1,
"metastatic renal cell carcinoma":1,
"pyruvate kinase muscle isozyme M2":1,
"AFAP1-AS1":1,
"Carcinogene":1,
"Carcinoma":1,
"Long non-coding RNA":1,
"Invasion":1,
"MAL2":1,
"Migration":1,
"epidermal growth factor receptor (EGFR)":1,
"lung adenocarcinoma":1,
"molecular studies":1,
"non-small cell lung carcinoma (NSCLC)":1,
"prognosis in thyroid transcription factor 1-negative non-small cell lung carcinoma":1,
"thyroid transcription factor 1 (TTF1)":1,
"thyroid transcription factor 1-negative lung adenocarcinoma":1,
"apoptosis":2,
"endoplasmic reticulum stress":1,
"nasopharyngeal carcinoma":1,
"carcinoid cancer":1,
"gastroenteropancreatic":1,
"lutetium Lu 177 dotatate":1,
"neuroendocrine tumors":1,
"fear of recurrence":1,
"population-based":1,
"prospective":1,
"color Doppler ultrasonography":1,
"diagnostic value":1,
"primary hepatic carcinoma":1,
"two-dimensional ultrasonography":1,
"cyclin D2":1,
"microRNA-409-3p":1,
"Chromogenic":1,
"Diagnosis":2,
"Multiplexed immunohistochemistry":1,
"Non-small cell lung cancer":1,
"Predictive biomarkers":1,
"Roux-en-Y reconstruction":1,
"distal jejunal pouch":1,
"total gastrectomy":1,
"Granular cell tumours of the neurohypophysis":1,
"Pituicytoma":1,
"Posterior pituitary tumours":1,
"Spindle cell oncocytoma":2,
"Aggressiveness":1,
"Cell adhesion":1,
"Papillary thyroid microcarcinoma":2,
"Somatic mutation":1,
"Whole-exome sequencing":1,
"EMT":1,
"FGF signaling":1,
"TKI":1,
"Thyroid malignancy":1,
"bilateral surgery":1,
"intraoperative neuromonitoring":1,
"invaded nerve":1,
"nerve preservation":1,
"nerve resection":1,
"only functional nerve":1,
"recurrent laryngeal nerve":1,
"thyroid surgery":1,
"vocal cord paralysis":1,
"Hippo":1,
"LATS":1,
"MOB1":1,
"NF2":1,
"Rho":1,
"YAP":1,
"phosphatidic acid":1,
"phospholipase D":1,
"C-cell":1,
"familial":1,
"medullary":2,
"sporadic":1,
"Dual malignancy":1,
"liver":1,
"mucosa-associated lymphoid tissue lymphoma":1,
"Incidental":1,
"Non-incidental":1,
"Modified radical neck dissection":1,
"cytology":1,
"I-131":1,
"scintigraphy":1,
"SPECT/CT":1,
"AFF3":1,
"Estrogen receptor-positive":1,
"Resistance":1,
"Tamoxifen":1,
"cohort studies":1,
"risk":1,
"sociodemographic":1,
"CXCL5":1,
"NKX2-1":1,
"SOX2":1,
"adenocarcinoma":1,
"mouse models":1,
"squamous":1,
"transdifferentiation":1,
"tumor immune microenvironment":1,
"tumor-associated neutrophils":1,
"biopsy":1,
"fine-needle aspiration (FNA)":1,
"Assodium/iodide symporter":1,
"Mitogen-activated protein kinase":1,
"Mutation BRAFV600E":1,
"Fine needle aspiration":1,
"Molecular marker":1,
"Proprotein convertase PACE4":1,
"B-Raf proto-oncogene":1,
"Gray-scale ultrasound":1,
"Level VI lymph nodes":1,
"Shear wave elastography":1,
"connective tissue disease":1,
"malignant and benign haematology":1,
"Gene therapy":1,
"Sodium iodide symporter":1,
"Theranostics":1,
"18F-FDG PET/CT":1,
"Axillary lymph node metastasis":1,
"Hürthle cell carcinoma of the thyroid":1,
"VEGF":1,
"antiangiogenesis":1,
"hypertension":1,
"osteopenia":1,
"postmenopausal women":1,
"thyroid-stimulating hormone suppression":1,
"The Cancer Genome Atlas":1,
"long noncoding RNAs":1,
"risk score":1,
"comparative genomics":1,
"flow sorting":1,
"intratumoral heterogeneity":1,
"metastatic tumor evolution":1,
"Anaplastic thyroid Cancer":1,
"Inhibitors":1,
"Therapeutics":1,
"Tumor":1,
"Hashinoto's disease":1,
"anti-thyroid antibodies":1,
"neck dissection":1,
"spinal accessory nerve":1,
"Cachexia":1,
"Exosomes":1,
"Tumour progression":1,
"Big data":1,
"Decision support system":1,
"Evidence based medicine":1,
"Forecasting":1,
"Genomics":1,
"Guidelines":2,
"Head and neck cancer":3,
"Machine learning":1,
"Oncology":2,
"Radiotherapy":4,
"Support vector machine":1,
"HCC":1,
"NASH":1,
"epidemiology":1,
"physiopathology":1,
"interobserver variation":1,
"risk of malignancy":1,
"sonography":1,
"Incidental carcinoma":1,
"Multiple endocrine neoplasia 2A":1,
"Prophylactic thyroidectomy":1,
"Recurrent carcinoma":1,
"Suture granuloma":1,
"HBXIP":1,
"miR-145":1,
"Thyroid micronodules":1,
"malignancy":1,
"elastography":1,
"strain index":1,
"Fluorodeoxyglucose positron emission tomography":1,
"histopathology report":1,
"intrathyroid metastasis":1,
"squamous cell carcinoma":1,
"Adrenal oncocytoma":1,
"fluorodeoxyglucose":1,
"magnetic resonance imaging":1,
"positron emission tomography/computed tomography":1,
"radioiodine scan":1,
"skeletal metastasis":1,
"Classification":1,
"Next generation sequencing":1,
"RNA sequencing":1,
"Anaplastic thyroid carcinoma":1,
"Bioinformatics":1,
"Cancer/testis gene":1,
"Chromosome segregation":1,
"Key genes identification":1,
"Meta-analysis of microarray datasets":1,
"Adverse effect":1,
"Benign Prostatic Hyperplasia":1,
"Prostate":1,
"Adverse events":1,
"anti-PD-1 antibody":1,
"dysphagia":1,
"parathyroidectomy":1,
"CASTLE":1,
"extrathyroidal tumor extension":1,
"thyroid tumor":1,
"IGFBP5":1,
"UCA1":1,
"lncRNA":1,
"miR-204":1,
"calcitonin":3,
"calcium gluconate":1,
"pentagastrin":1,
"ROS1 rearrangement":1,
"carcinoma of unknown primary site":1,
"crizotinib":1,
"putative lung adenocarcinoma":1,
"Mandible":1,
"Maxilla":1,
"Microvascular reconstruction":1,
"Osseous reconstruction":1,
"ECLIA":1,
"Electrochemiluminescence immunoassay":1,
"Fine-needle aspiration washout fluid":1,
"Influencing factors":1,
"Matched case-control study":1,
"Ethanol ablation":1,
"Radiofrequency ablation":1,
"MTDH":1,
"lobaplatin":1,
"BRAF":1,
"Malignant papillary thyroid carcinoma":1,
"Struma ovarii":1,
"CN = cranial nerve":1,
"CNS = central nervous system":1,
"EMA = epithelial membrane antigen":1,
"GFAP = glial fibrillary acidic protein":1,
"GTR = gross-total resection":1,
"OSH = outside hospital":1,
"S100 = S100 protein":1,
"SCO = spindle cell oncocytoma":1,
"TS = transsphenoidal":1,
"TTF-1 = thyroid transcription factor 1":1,
"WHO = World Health Organization":1,
"neurosurgery":1,
"pituitary surgery":1,
"transsphenoidal":1,
"Branchial cleft cysts":1,
"congenital defect":1,
"fine-needle biopsy":1,
"Antituberculous therapy":1,
"Clinical presentation":1,
"Granulomatous lobular mastitis":1,
"Management":1,
"Completion thyroidectomy":1,
"postoperative complication":1,
"Neoadjuvant chemotherapy":1,
"Preoperative circulating neutrophil–lymphocyte ratio":1,
"Primary bladder cancer":1,
"Radical cystectomy":1,
"Unfavorable outcome":1,
"time until recurrence of the disease":1,
"EQ5D":1,
"cancer site":1,
"cancer survivors":1,
"BRAF V600E gene":1,
"pathological examination":1,
"lymphatic metastasis":1,
"piriform fossa cancer":1,
"postoperative pharyngeal fistula":1,
"thyroid lobes":1,
"Chernobyl":1,
"radiation":1,
"radioactivity":1,
"surveys and questionnaires":1,
"Graves’ disease":1,
"Marine‐Lenhart syndrome":1,
"hot thyroid nodule":1,
"EGFR":1,
"HPV":1,
"P16":1,
"accelerated":1,
"cyclin D1":1,
"genetics":1,
"hyperfractionated":1,
"radiation therapy":1,
"translational research":1,
"Lifetime risk":1,
"medulloblastoma":1,
"pediatric patients":1,
"secondary cancer":1,
"Diffusion-weighted imaging":1,
"diffusion-weighted whole-body imaging with background body signal suppression":1,
"imaging":1,
"obstetrics":1,
"pregnancy":1,
"NMR-based metabolomics":1,
"CEA":1,
"Calcitonin doubling time":1,
"Multiple endocrine neoplasia":1,
"MEN":1,
"head and neck neoplasms":1,
"marginal zone B-cell lymphoma":1,
"mucosa-associated lymphoid tissue":1,
"histopathology":1,
"neuroendocrine markers":1,
"pathologic diagnosis":1            };
            var data = [];
            for (var name in keywords) {
                data.push({
                    name: name,
                    value: Math.sqrt(keywords[name])
                })
            }
            var maskImage = new Image();
            var option = {
	             title: {
                text: '2018年10月论文keyword词云'
            },
                series: [ {
                    type: 'wordCloud',
                    sizeRange: [15, 100],
                    rotationRange: [-90, 90],
                    rotationStep: 45,
                    gridSize: 2,
                    shape: 'pentagon',
                    maskImage: maskImage,
                    drawOutOfBound: false,
                    textStyle: {
                        normal: {
                            color: function () {
                                return 'rgb(' + [
                                    Math.round(Math.random() * 160),
                                    Math.round(Math.random() * 160),
                                    Math.round(Math.random() * 160)
                                ].join(',') + ')';
                            }
                        },
                        emphasis: {
                            color: 'red'
                        }
                    },
                    data: data.sort(function (a, b) {
                        return b.value  - a.value;
                    })
                } ]
            };
            maskImage.onload = function () {
                option.series[0].maskImage
                chart.setOption(option);
            }
            maskImage.src = 'data:image/png;base64,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';
            window.onresize = function () {
                chart.resize();
            }
        </script>
    </body>
</html>
